Borne Ryan T, Varosy Paul, Lan Zhou, Masoudi Frederick A, Curtis Jeptha P, Matlock Daniel D, Peterson Pamela N
Division of Cardiology, University of Colorado Health, Colorado Springs.
Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora.
JAMA Netw Open. 2022 Mar 1;5(3):e223429. doi: 10.1001/jamanetworkopen.2022.3429.
Use of dual-chamber implantable cardioverter-defibrillator (ICD) systems among patients without a pacing indication is an example of low-value care given higher procedural risks, higher costs, and little evidence for benefit from an atrial lead. However, variation in the use of dual-chamber systems was present among patients without a pacing indication.
To examine the temporal trends and hospital variation in use of single- and dual-chamber ICD implantation among patients without a pacing indication undergoing first-time ICD implantation.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter cross-sectional study was conducted using the US National Cardiovascular Data Registry ICD Registry. A total of 266 182 patients undergoing initial implantation of a single- or dual-chamber transvenous ICD without a bradycardia pacing indication, class I or II cardiac resynchronization therapy indication, or history of atrial fibrillation or atrial flutter were included. The study was conducted from April 1, 2010, to December 31, 2018; data analysis was performed from October 19, 2020, to January 5, 2022.
Implantation of a single- or dual-chamber ICD.
Temporal trends among patients undergoing single- vs dual-chamber ICDs were determined using the Cochran-Armitage trend test, and hospital-level variation using adjusted hospital median odds ratios was examined.
A total of 266 182 patients (single-chamber ICD, 134 925; dual-chamber ICD, 131 257) were included in this analysis; mean (SD) age was 58.0 (14.0) years and 91 990 patients (68.2%) were men. The use of dual-chamber ICDs decreased from 64.7% (n = 15 694) in 2010 to 42.2% (n = 9762) in 2018 (P < .001). Adjusted for patient characteristics, the median hospital-level proportion of single-chamber ICDs increased from 42.9% (95% CI, 42.6%-45.0%) in 2010 to 50.0% (95% CI, 47.8%-51.0%) in 2018. The median odds ratio for the use of dual-chamber ICDs, adjusted for patient characteristics, was 1.6 (95% CI, 1.6-1.8) in 2010 and 1.5 (95% CI, 1.5-1.8) in 2018, indicating decreasing but persistent variation in use.
In this national study of US patients undergoing first-time ICD implantation without a clinical indication for an atrial lead, the use of dual-chamber devices decreased. However, institutional variability in the use of atrial leads persists, suggesting differences in individual or institutional cultures of real-world practice and opportunity to reduce this low-value practice.
对于无起搏指征的患者使用双腔植入式心脏复律除颤器(ICD)系统,鉴于其较高的手术风险、更高的成本以及几乎没有证据表明心房导线能带来益处,是低价值医疗的一个例子。然而,在无起搏指征的患者中,双腔系统的使用存在差异。
研究首次植入ICD且无起搏指征的患者中,单腔和双腔ICD植入的时间趋势及医院间差异。
设计、设置和参与者:使用美国国家心血管数据注册中心ICD注册库进行了一项多中心横断面研究。纳入了总共266182例首次植入单腔或双腔经静脉ICD且无心动过缓起搏指征、I类或II类心脏再同步治疗指征、或房颤或房扑病史的患者。研究于2010年4月1日至2018年12月31日进行;数据分析于2020年10月19日至2022年1月5日进行。
单腔或双腔ICD植入。
使用 Cochr an - Armitage趋势检验确定接受单腔与双腔ICD患者的时间趋势,并使用调整后的医院中位数优势比检查医院层面的差异。
本分析共纳入266182例患者(单腔ICD,134925例;双腔ICD,131257例);平均(标准差)年龄为58.0(14.0)岁,91990例患者(68.2%)为男性。双腔ICD的使用从2010年的64.7%(n = 15694)降至2018年的42.2%(n = 9762)(P <.001)。根据患者特征进行调整后,单腔ICD在医院层面的中位数比例从2010年的42.9%(95% CI,42.6% - 45.0%)增至2018年的50.0%(95% CI,47.8% - 51.0%)。根据患者特征调整后,2010年双腔ICD使用的中位数优势比为1.6(95% CI,1.6 - 1.8),2018年为1.5(95% CI,1.5 - 1.8),表明使用差异虽在减少但仍持续存在。
在这项针对美国首次植入ICD且无临床心房导线指征患者的全国性研究中,双腔设备的使用减少了。然而,心房导线使用的机构差异仍然存在,这表明在实际临床实践中个体或机构文化存在差异,并且有机会减少这种低价值医疗行为。